RESUMO
Candida auris is an emerging fungal pathogen that exhibits resistance to multiple drugs, including the most commonly prescribed antifungal, fluconazole. Here, we use a combinatorial screening approach to identify a bis-benzodioxolylindolinone (azoffluxin) that synergizes with fluconazole against C. auris. Azoffluxin enhances fluconazole activity through the inhibition of efflux pump Cdr1, thus increasing intracellular fluconazole levels. This activity is conserved across most C. auris clades, with the exception of clade III. Azoffluxin also inhibits efflux in highly azole-resistant strains of Candida albicans, another human fungal pathogen, increasing their susceptibility to fluconazole. Furthermore, azoffluxin enhances fluconazole activity in mice infected with C. auris, reducing fungal burden. Our findings suggest that pharmacologically targeting Cdr1 in combination with azoles may be an effective strategy to control infection caused by azole-resistant isolates of C. auris.
Assuntos
Azóis/farmacologia , Candida/patogenicidade , Oxindóis/farmacologia , Animais , Antifúngicos/análise , Antifúngicos/química , Antifúngicos/farmacologia , Azóis/análise , Azóis/química , Candida/efeitos dos fármacos , Candida/isolamento & purificação , Avaliação Pré-Clínica de Medicamentos , Sinergismo Farmacológico , Fluconazol/farmacologia , Proteínas Fúngicas/metabolismo , Deleção de Genes , Humanos , Camundongos , Oxindóis/química , Virulência/efeitos dos fármacosRESUMO
NDV-3A, a novel fungal vaccine undergoing clinical trials, contains a recombinant version of the Candida albicans rAls3 N-terminus protein (rAls3p-N) in aluminum hydroxide. In a Phase 1b/2a clinical trial, NDV-3A protected women from recurrent vulvovaginal candidiasis. Here, we reveal that active immunization in mice with NDV-3A induces high titers of anti-rAls3p-N antibodies that interfere with C. albicans ability to adhere to and invade endothelial cells, and form biofilm in vitro. Anti-rAls3p-N antibodies also significantly inhibit yeast dispersal from the hyphal layers of biofilms. Compared to placebo, NDV-3A vaccination inhibited C. albicans dissemination to kidneys and prevented colonization of central venous catheters in mice. Overall, these preclinical studies suggest that NDV-3A may serve as an immunotherapeutic strategy for prevention of infections on indwelling medical devices.
Assuntos
Anticorpos Antifúngicos/farmacologia , Proteínas Fúngicas/imunologia , Vacinas Fúngicas/uso terapêutico , Vacinação/métodos , Animais , Anticorpos Antifúngicos/imunologia , Biofilmes/efeitos dos fármacos , Candida albicans/efeitos dos fármacos , Candida albicans/imunologia , Adesão Celular/efeitos dos fármacos , Cateteres Venosos Centrais/microbiologia , Vacinas Fúngicas/farmacologia , Humanos , Controle de Infecções , Camundongos , Proteínas RecombinantesRESUMO
Background: Recurrent vulvovaginal candidiasis (RVVC) is a problematic form of mucosal Candida infection, characterized by repeated episodes per year. Candida albicans is the most common cause of RVVC. Currently, there are no immunotherapeutic treatments for RVVC. Methods: This exploratory randomized, double-blind, placebo-controlled trial evaluated an immunotherapeutic vaccine (NDV-3A) containing a recombinant C. albicans adhesin/invasin protein for prevention of RVVC. Results: The study in 188 women with RVVC (n = 178 evaluable) showed that 1 intramuscular dose of NDV-3A was safe and generated rapid and robust B- and T-cell immune responses. Post hoc exploratory analyses revealed a statistically significant increase in the percentage of symptom-free patients at 12 months after vaccination (42% vaccinated vs 22% placebo; P = .03) and a doubling in median time to first symptomatic episode (210 days vaccinated vs 105 days placebo) for the subset of patients aged <40 years (n = 137). The analysis of evaluable patients, which combined patients aged <40 years (77%) and ≥40 years (23%), trended toward a positive impact of NDV-3A versus placebo (P = .099). Conclusions: In this unprecedented study of the effectiveness of a fungal vaccine in humans, NDV-3A administered to women with RVVC was safe and highly immunogenic and reduced the frequency of symptomatic episodes of vulvovaginal candidiasis for up to 12 months in women aged <40 years. These results support further development of NDV-3A vaccine and provide guidance for meaningful clinical endpoints for immunotherapeutic management of RVVC. Clinical Trials Registration: NCT01926028.
Assuntos
Candidíase Vulvovaginal/terapia , Proteínas Fúngicas/uso terapêutico , Vacinas Fúngicas/uso terapêutico , Imunoterapia , Adolescente , Adulto , Linfócitos B/imunologia , Candida albicans/efeitos dos fármacos , Candidíase Vulvovaginal/imunologia , Método Duplo-Cego , Feminino , Vacinas Fúngicas/efeitos adversos , Humanos , Imunogenicidade da Vacina , Injeções Intramusculares , Pessoa de Meia-Idade , Recidiva , Linfócitos T/imunologia , Adulto JovemRESUMO
OBJECTIVES: Previously we demonstrated the benefit of isavuconazole in treating murine mucormycosis due to Rhizopus. We wanted to determine the efficacy of isavuconazole in treating murine mucormycosis caused by Mucor, the second most common cause of the disease. Furthermore, because we previously determined that Rhizopus possesses the target enzyme for echinocandins and micafungin has activity against murine mucormycosis, we compared the activity of combination therapy (isavuconazoleâ+âmicafungin) with placebo, either drug alone or standard therapy of liposomal amphotericin B (LAmB) in treating pulmonary murine mucormycosis caused by Rhizopus delemar. METHODS: In vitro susceptibility to isavuconazole of Mucorales was evaluated using the CLSI M38-A2 method. Immunosuppressed mice were intratracheally infected with either Mucor circinelloides or R. delemar. Treatment with isavuconazole (orally), micafungin (intraperitoneally), a combination of both or LAmB (intravenously) was compared, with survival and tissue fungal burden serving as primary and secondary endpoints, respectively. RESULTS: Isavuconazole was as effective as LAmB in prolonging survival of mice infected with M. circinelloides. Against R. delemar-induced mucormycosis, all monotherapy treatments significantly improved survival of mice versus placebo without showing superiority over one another. However, LAmB was superior in lowering fungal burden in target organs. Although combination therapy of isavuconazoleâ+âmicafungin did not enhance survival of mice over monotherapy, antagonism was not detected between the two drugs. CONCLUSION: Isavuconazole is effective in treating pulmonary murine mucormycosis due to Mucor. In addition, combination therapy of isavuconazoleâ+âmicafungin does not demonstrate synergy and it is not antagonistic against Rhizopus-induced mucormycosis.
Assuntos
Antifúngicos/uso terapêutico , Equinocandinas/uso terapêutico , Lipopeptídeos/uso terapêutico , Mucor/efeitos dos fármacos , Mucormicose/tratamento farmacológico , Nitrilas/uso terapêutico , Piridinas/uso terapêutico , Rhizopus/efeitos dos fármacos , Triazóis/uso terapêutico , Animais , Quimioterapia Combinada , Pulmão/microbiologia , Masculino , Micafungina , Camundongos , Testes de Sensibilidade MicrobianaRESUMO
Patients with diabetic ketoacidosis (DKA) are uniquely predisposed to mucormycosis, an angioinvasive fungal infection with high mortality. Previously, we demonstrated that Rhizopus invades the endothelium via binding of fungal CotH proteins to the host receptor GRP78. Here, we report that surface expression of GRP78 is increased in endothelial cells exposed to physiological concentrations of ß-hydroxy butyrate (BHB), glucose, and iron that are similar to those found in DKA patients. Additionally, expression of R. oryzae CotH was increased within hours of incubation with DKA-associated concentrations of BHB, glucose, and iron, augmenting the ability of R. oryzae to invade and subsequently damage endothelial cells in vitro. BHB exposure also increased fungal growth and attenuated R. oryzae neutrophil-mediated damage. Further, mice given BHB developed clinical acidosis and became extremely susceptible to mucormycosis, but not aspergillosis, while sodium bicarbonate reversed this susceptibility. BHB-related acidosis exerted a direct effect on both GRP78 and CotH expression, an effect not seen with lactic acidosis. However, BHB also indirectly compromised the ability of transferrin to chelate iron, as iron chelation combined with sodium bicarbonate completely protected endothelial cells from Rhizopus-mediated invasion and damage. Our results dissect the pathogenesis of mucormycosis during ketoacidosis and reinforce the importance of careful metabolic control of the acidosis to prevent and manage this infection.
Assuntos
Cetoacidose Diabética/tratamento farmacológico , Mucormicose/tratamento farmacológico , Bicarbonato de Sódio/uso terapêutico , Ácido 3-Hidroxibutírico/toxicidade , Animais , Cetoacidose Diabética/complicações , Cetoacidose Diabética/metabolismo , Modelos Animais de Doenças , Chaperona BiP do Retículo Endoplasmático , Células Endoteliais/efeitos dos fármacos , Células Endoteliais/metabolismo , Células Endoteliais/microbiologia , Proteínas Fúngicas/genética , Proteínas Fúngicas/metabolismo , Glucose/metabolismo , Proteínas de Choque Térmico/genética , Proteínas de Choque Térmico/metabolismo , Interações Hospedeiro-Patógeno/efeitos dos fármacos , Interações Hospedeiro-Patógeno/genética , Interações Hospedeiro-Patógeno/fisiologia , Humanos , Ferro/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos ICR , Mucormicose/etiologia , Mucormicose/metabolismo , Rhizopus/efeitos dos fármacos , Rhizopus/genética , Rhizopus/patogenicidade , Virulência/efeitos dos fármacosRESUMO
Dialysis patients with chronic renal failure receiving deferoxamine for treating iron overload are uniquely predisposed for mucormycosis, which is most often caused by Rhizopus oryzae. Although the deferoxamine siderophore is not secreted by Mucorales, previous studies established that Rhizopus species utilize iron from ferrioxamine (iron-rich form of deferoxamine). Here we determined that the CBS domain proteins of Fob1 and Fob2 act as receptors on the cell surface of R. oryzae during iron uptake from ferrioxamine. Fob1 and Fob2 cell surface expression was induced in the presence of ferrioxamine and bound radiolabeled ferrioxamine. A R. oryzae strain with targeted reduced Fob1/Fob2 expression was impaired for iron uptake, germinating, and growing on medium with ferrioxamine as the sole source of iron. This strain also exhibited reduced virulence in a deferoxamine-treated, but not the diabetic ketoacidotic (DKA), mouse model of mucormycosis. The mechanism by which R. oryzae obtains iron from ferrioxamine involves the reductase/permease uptake system since the growth on ferrioxamine supplemented medium is associated with elevated reductase activity and the use of the ferrous chelator bathophenanthroline disulfonate abrogates iron uptake and growth on medium supplemented with ferrioxamine as a sole source of iron. Finally, R. oryzae mutants with reduced copies of the high affinity iron permease (FTR1) or with decreased FTR1 expression had an impaired iron uptake from ferrioxamine in vitro and reduced virulence in the deferoxamine-treated mouse model of mucormycosis. These two receptors appear to be conserved in Mucorales, and can be the subject of future novel therapy to maintain the use of deferoxamine for treating iron-overload.
Assuntos
Proteínas de Ligação a DNA/metabolismo , Desferroxamina/metabolismo , Compostos Férricos/metabolismo , Ferro/metabolismo , Glicoproteínas de Membrana/metabolismo , Mucormicose/tratamento farmacológico , Rhizopus/metabolismo , Proteínas de Saccharomyces cerevisiae/metabolismo , Fatores de Virulência/metabolismo , Animais , Transporte Biológico/efeitos dos fármacos , Transporte Biológico/fisiologia , Quelantes de Ferro/farmacologia , Proteínas de Membrana Transportadoras/metabolismo , Camundongos , Mucormicose/microbiologia , Sideróforos/metabolismoRESUMO
OBJECTIVES: Increased bone marrow iron levels in patients with haematological malignancies is an independent risk factor for developing invasive pulmonary aspergillosis (IPA), suggesting an important role for iron uptake in the pathogenesis of IPA. We sought to determine the potential for combination therapy with the iron chelator deferasirox + liposomal amphotericin B (LAmB) to improve the outcome of murine IPA compared with LAmB monotherapy. METHODS: In vitro MIC and minimum fungicidal concentration (MFC) values of the iron chelator, deferasirox, for Aspergillus fumigatus were determined by microdilution assay. In addition, we studied the efficacy of deferasirox alone or combined with LAmB in treating immunocompromised mice infected with A. fumigatus via inhalation. RESULTS: Deferasirox was cidal in vitro against A. fumigatus, with an MIC and MFC of 25 and 50 mg/L, respectively. Deferasirox monotherapy modestly prolonged survival of mice with IPA. Combination deferasirox + LAmB therapy synergistically improved survival and reduced lung fungal burden compared with either monotherapy alone. CONCLUSIONS: Iron chelation therapy with deferasirox alone or in combination with LAmB is effective in treating experimental IPA. Further study of deferasirox is warranted as adjunctive therapy for IPA infections.
Assuntos
Anfotericina B/uso terapêutico , Antifúngicos/uso terapêutico , Benzoatos/uso terapêutico , Aspergilose Pulmonar Invasiva/tratamento farmacológico , Triazóis/uso terapêutico , Anfotericina B/farmacologia , Animais , Aspergillus fumigatus/efeitos dos fármacos , Benzoatos/farmacologia , Deferasirox , Sinergismo Farmacológico , Quimioterapia Combinada , Humanos , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Testes de Sensibilidade Microbiana , Viabilidade Microbiana , Análise de Sobrevida , Resultado do Tratamento , Triazóis/farmacologiaRESUMO
OBJECTIVES: Patients treated with the iron chelator deferoxamine are known to be more susceptible to mucormycosis. However, while deferoxamine is an iron chelator from the perspective of the human host, deferoxamine actually serves as a siderophore, delivering free iron to Rhizopus oryzae, the major cause of mucormycosis. Other iron chelators, including deferiprone, which do not deliver iron to R. oryzae have been described. We therefore sought to determine whether iron-chelation therapy with deferiprone would effectively treat mucormycosis. METHODS: In vitro MIC and minimum fungicidal concentration (MFC) of the iron chelator, deferiprone, for R. oryzae were determined by microdilution assay. In addition, we compared the efficacy of deferiprone with that of liposomal amphotericin B (LAmB) in treating mucormycosis in diabetic ketoacidotic mice. RESULTS: Deferiprone demonstrated static activity against R. oryzae at 24 h, but showed cidality at 48 h of incubation. Deferiprone was as effective as LAmB at improving survival and decreasing brain fungal burden, and both drugs were more effective than placebo in non-iron-overloaded animals. Administration of free iron with deferiprone reversed protection, confirming that the mechanism of protection was iron chelation. CONCLUSIONS: Iron chelation is a promising, novel therapeutic strategy for refractory mucormycosis infections. Further studies are warranted to evaluate combination antifungal/iron chelation therapy and to evaluate the efficacy of other iron-chelating agents.
Assuntos
Quelantes de Ferro/farmacologia , Mucormicose/tratamento farmacológico , Piridonas/farmacologia , Rhizopus/efeitos dos fármacos , Anfotericina B/farmacologia , Animais , Antifúngicos/farmacologia , Deferiprona , Cetoacidose Diabética/microbiologia , Humanos , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Testes de Sensibilidade Microbiana , Mucormicose/microbiologia , Rhizopus/isolamento & purificaçãoRESUMO
Rhizopus oryzae is the most common cause of zygomycosis, a life-threatening infection that usually occurs in patients with diabetic ketoacidosis. Despite standard therapy, the overall rate of mortality from zygomycosis remains >50%, and new strategies for treatment are urgently needed. The activities of caspofungin acetate (CAS) and other echinocandins (antifungal inhibitors of the synthesis of 1,3-beta-D-glucan synthase [GS]) against the agents of zygomycosis have remained relatively unexplored, especially in animal models of infection. We found that R. oryzae has both an FKS gene, which in other fungi encodes a subunit of the GS synthesis complex, and CAS-susceptible, membrane-associated GS activity. Low-dose but not high-dose CAS improved the survival of mice with diabetic ketoacidosis infected with a small inoculum but not a large inoculum of R. oryzae. Fungal burden, assessed by a novel quantitative PCR assay, correlated with increasing inocula and progression of disease, particularly later in the infection, when CFU counts did not. CAS decreased the brain burden of R. oryzae when it was given prophylactically but not when therapy was started after infection. These results indicate that CAS has significant but limited activity against R. oryzae in vivo and demonstrates an inverse dose-response effect. The potential for CAS to play a role in combination therapy against zygomycosis merits further investigation.
Assuntos
Antifúngicos/farmacologia , Antifúngicos/uso terapêutico , Encéfalo/microbiologia , Glucosiltransferases/antagonistas & inibidores , Mucormicose/tratamento farmacológico , Peptídeos Cíclicos/farmacologia , Peptídeos Cíclicos/uso terapêutico , Rhizopus/enzimologia , Zigomicose/tratamento farmacológico , Sequência de Aminoácidos , Anfotericina B/farmacologia , Animais , Antifúngicos/administração & dosagem , Southern Blotting , Encéfalo/patologia , Caspofungina , Contagem de Colônia Microbiana , DNA Fúngico/genética , DNA Fúngico/isolamento & purificação , Cetoacidose Diabética/complicações , Relação Dose-Resposta a Droga , Equinocandinas , Genes Fúngicos , Lipopeptídeos , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Dados de Sequência Molecular , Mucormicose/microbiologia , Peptídeos Cíclicos/administração & dosagem , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Rhizopus/efeitos dos fármacos , Sobrevida , Zigomicose/microbiologia , Zigomicose/mortalidadeRESUMO
Platelet microbicidal proteins (PMPs) are believed to be integral to host defense against endovascular infection. We previously demonstrated that susceptibility to thrombin-induced PMP 1 (tPMP-1) in vitro negatively influences Candida albicans virulence in the rabbit model of infective endocarditis (IE). This study evaluated the relationship between in vitro tPMP-1 susceptibility (tPMP-1s) or resistance (tPMP-1r) and efficacy of fluconazole (FLU) therapy of IE due to C. albicans. Candida IE was established in rabbits with either tPMP-1s or tPMP-1r strains. Treatment groups received FLU (100 mg/kg/day) intraperitoneally for 7 or 14 days; control animals received no therapy. At these time points, cardiac vegetations, kidneys, and spleens were quantitatively cultured to assess fungal burden. At both 7 and 14 days and in all target tissues, the extent of candidal clearance by FLU was greater in animals infected with the tPMP-1s strain than in those infected with the tPMP-1r strain. These differences were statistically significant in the spleen and kidney. Corroborating these in vivo data, FLU (a candidastatic agent), in combination with tPMP-1, exerted an enhanced fungicidal effect in vitro against tPMP-1s and tPMP-1r C. albicans, with the extent of this effect greatest against the tPMP-1s strain. Collectively, these results support the concept that tPMP-1 susceptibility contributes to the net efficacy of FLU against C. albicans IE in vivo, particularly in tissues in which platelets and tPMP-1 likely play significant roles in host defense.
Assuntos
Antifúngicos/uso terapêutico , Proteínas Sanguíneas/uso terapêutico , Candidíase/tratamento farmacológico , Endocardite/tratamento farmacológico , Fluconazol/uso terapêutico , Animais , Proteínas Sanguíneas/farmacologia , Candida albicans/efeitos dos fármacos , Candidíase/microbiologia , Contagem de Colônia Microbiana , Avaliação Pré-Clínica de Medicamentos , Sinergismo Farmacológico , Endocardite/microbiologia , Coração/microbiologia , Rim/microbiologia , Testes de Sensibilidade Microbiana , Especificidade de Órgãos , Coelhos , Especificidade da Espécie , Baço/microbiologiaRESUMO
The efficacies of liposomal amphotericin B (LAmB) and amphotericin B deoxycholate (AmB) were compared in a diabetic murine model of hematogenously disseminated Rhizopus oryzae infection. At 7.5 mg/kg of body weight twice a day (b.i.d.), LAmB significantly improved overall survival compared to the rates of survival in both untreated control mice (P = 0.001) and mice treated with 0.5 mg of AmB per kg b.i.d. (P = 0.047). These data indicate that high-dose LAmB is more effective than AmB in treating murine disseminated zygomycosis.